Total revenues for the quarter ended June 30, 2008 increased by $656.8 million to $1.20 billion from $546.3 million in the same prior year period. Approximately $669.3 million represents amounts contributed through the acquisition of Merck Generics.
Generics Segment revenues were $992.9 million and are derived from sales in Europe, the Middle East & Africa (collectively, "EMEA"), North America and Asia Pacific.
Total revenues from North America were $461.8 million for the three months ended June 30, 2008 compared to $455.0 million for the same prior year period, representing an increase of $6.8 million. Revenues of approximately $32.4 million were realized in North America in the current quarter as a result of the acquisition of Merck Generics. Excluding these amounts, total revenues decreased by $25.6 million from the same prior year period.
This decrease in revenues is driven by the timing of exclusive product launches and overall unfavorable pricing, partially offset by favorable volume and revenue from new products. In the current year, new products launched in the U.S. contributed revenues of $75.6 million, consisting primarily of paroxetine ER and felodipine ER. In the prior year, the Company received a significant contribution to revenue from amlodipine and oxybutynin, both of which had exclusivity for a portion of the quarter. Generic competition on certain products in the Company's portfolio, including amlodipine, was responsible for the unfavorable pricing realized in the current period.
Total revenues from EMEA and Asia Pacific, as well as revenues from the
Specialty Segment, were all the result of the acquisition of Merck
Generics. For EMEA, revenues for the quarter ended June 30, 2008 were
$389.8 million, the majority of which are derived from the three largest
|SOURCE Mylan Inc.|
Copyright©2008 PR Newswire.
All rights reserved